FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Foghorn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.87+0.02 (+1.08%)
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Foghorn Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -198.0%
- Net margin
- -175.8%
- Return on equity, FY2025
- 96.5%
Financial strength
- Current ratio
- 3.36
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 134.6%
Valuation
- P/E ratio
- –
- Price to sales
- 3.60
- Price to book
- –
- Dividend yield
- –